ISA Pharmaceuticals Appoints Hendrik-Jan Laseur as Member of the Supervisory Board
September 03, 2014
ISA Pharmaceuticals Appoints Hendrik-Jan Laseur as Member of the Supervisory Board
Leiden, The Netherlands, September 3, 2014 – ISA Pharmaceuticals B.V., a clinical-stage immunotherapy company focusing on rationally designed immunotherapeutics against cancer and persistent viral infections, today announced the appointment of Hendrik-Jan Laseur to its Supervisory Board.
Hendrik-Jan Laseur has an outstanding track record in advising foundations, non-governmental organizations and financial institutions. Among others, he currently serves as a Board member of the Center for Public Integrity (Washington, DC, USA), as a member of the Advisory Board of SustainAbility (London, UK) and as a Board member of the Adessium Foundation (Rotterdam, The Netherlands).
Hendrik-Jan Laseur is the founder of Laseur – Lead the Change, an Amsterdam-based strategy advisory firm focused on supporting leaders in achieving lasting social impact of investments and business propositions. Clients include non-governmental organizations, civil society organizations, philanthropic foundations, financial institutions, and the United Nations.
Prior to founding Laseur in 2010, he was Principal Advisor of the Executive Director at UNICEF, where he worked on resource allocation, strategy, finance and funding issues.
From 1992 to 2007, Hendrik-Jan Laseur worked at ABN Amro Bank in a variety of leadership and advisory positions in Tokyo, Frankfurt, London, Amsterdam and Zurich, including roles as personal secretary to the Chairman of the bank, and as a member of the Executive Committee of ABN AMRO Switzerland.
Hendrik-Jan Laseur studied economics in Groningen and Rotterdam and holds an MBA from INSEAD.
"We are delighted about Hendrik-Jan Laseur joining ISA Pharmaceuticals´ Supervisory Board as he brings extensive expertise in finance and strategy," said Pieter van der Meijden, Chairman of ISA´s Supervisory Board. "He will be an excellent successor to Ronald Loggers, who recently transitioned from ISA´s Supervisory Board to Chief Executive Officer of the company."
"I am convinced that ISA Pharmaceuticals can make a significant contribution to improving cancer therapy and the treatment of viral infections," said Hendrik-Jan Laseur. “Both areas are rising health challenges which urgently require novel treatment options. Therefore, I am looking forward to supporting the ISA team in advancing its proprietary immunotherapeutics.”
About ISA Pharmaceuticals
ISA Pharmaceuticals B.V. is an immunotherapy company developing rationally designed, fully synthetic therapeutic vaccines against cancer and persistent viral infections. The company has built a proprietary vaccine platform based on the Synthetic Long Peptide (SLP®) and AMPLIVANT® technologies, which enable the generation of safe and effective vaccines with a known mechanism of action. SLP® vaccines are broadly applicable to multiple targets and ideally suited as monotherapy or as essential components in combination with conventional cancer treatments or novel immunomodulators. SLP® vaccine therapies are capable of fully harnessing and directing the body‘s own defense towards fighting the disease.
ISA101, an SLP® vaccine targeting human papillomavirus (HPV)-induced diseases, is currently in clinical development in cervical cancer and anal intraepithelial neoplasia (AIN). Clinical proof-of-concept has been established with ISA101 in vulvar intraepithelial neoplasia (VIN), a pre-cancerous disease caused by HPV.
The company was founded in 2004 by Aglaia Oncology Fund and is based in Leiden, The Netherlands. For more information, please visit www.isa-pharma.com
AMPLIVANT® is a registered trademark in Europe.
Contact & Media Inquiries:
akampion
Dr. Ludger Wess, Managing Partner
Tel. +49 40 88 16 59 64
Ines-Regina Buth, Managing Partner
Tel. +49 30 23 63 27 68
